中国局限期小细胞肺癌高剂量超分割同步推量放疗对比标准剂量放疗:多中心、开放标签、3期随机试验
这项在中国16家公立医院开展的多中心、开放标签、3期随机试验,纳入224例18-70岁、ECOG 0-1、初治或仅接受1程顺铂或卡铂联合依托泊苷的局限期小细胞肺癌患者,1:1随机接受45 Gy(30次)或54 Gy(30次)同步推量VMAT胸部放疗,均每周10次每日两次,可反应者接受预防性颅脑放疗(25 Gy/10次)。中位随访46个月,54 Gy组中位总生存60.7个月(95%CI 49.2-62.0)显著长于45 Gy组39.5个月(27.5-51.4)(HR 0.55,95%CI 0.37-0.72;p=0.003)。两组化疗及放疗相关毒性相似,54 Gy组仅1例治疗相关死亡(心肌梗死)。研究因独立数据安全监查委员会认定临床获益充分而于2021年4月30日提前终止。
要点
- 54 Gy组中位总生存60.7个月(95%CI 49.2-62.0)vs 45 Gy组39.5个月(27.5-51.4),HR 0.55(95%CI 0.37-0.72),p=0.003。
- 两组3-4级放射性食管炎:54 Gy组14/108(13%)vs 45 Gy组14/116(12%),p=0.84;3-4级放射性肺炎:5/108(5%)vs 7/116(6%),p=0.663。
- 54 Gy组仅1例治疗相关死亡(心肌梗死),两组化疗相关与放疗相关毒性相似。
- 研究因独立数据安全监查委员会认定临床获益充分,于2021年4月30日提前终止。
- 作者结论支持将每日两次加速胸部放疗54 Gy联合化疗作为局限期小细胞肺癌一线替代治疗选择。
适用人群与场景
- 年龄18-70岁、组织学或细胞学确诊的局限期小细胞肺癌患者。
- ECOG体能状态评分0-1。
- 既往未治疗或仅接受过1程顺铂或卡铂联合依托泊苷化疗。
- 场景:中国16家公立医院,一线同步放化疗。
诊断标准与关键阈值
- 分期:局限期小细胞肺癌。
- 体能状态:ECOG 0-1。
- 既往治疗:未治疗或仅1程顺铂或卡铂联合依托泊苷。
- 年龄界值:18-70岁。
处置流程与药物剂量
- 放疗技术:容积调强弧形放疗(VMAT)。
- 54 Gy组:原发肿瘤区同步推量54 Gy/30次;45 Gy组:原发肿瘤区45 Gy/30次;两组计划靶区均为45 Gy/30次。
- 两组均每周10次胸部放疗,每日两次。
- 放疗于第一程化疗开始后0-42天内启动。
- 化疗方案:顺铂或卡铂联合依托泊苷(原文未写明具体剂量与疗程数)。
- 可反应者接受预防性颅脑放疗25 Gy/10次。
红旗征与不能漏的情况
- 54 Gy组发生1例治疗相关死亡(心肌梗死)。
研究设计与关键结果
- 研究类型:多中心、开放标签、3期随机试验;16家中国公立医院;样本量224例(女性102例[46%],男性122例[54%];中位年龄64岁[IQR 58-68]);54 Gy组108例,45 Gy组116例。
- 中位随访46个月(IQR 33-56)。
- 主要终点(意向治疗人群总生存):54 Gy组中位总生存60.7个月(95%CI 49.2-62.0)vs 45 Gy组39.5个月(95%CI 27.5-51.4);HR 0.55(95%CI 0.37-0.72);p=0.003。
- 3-4级放射性食管炎:54 Gy组14/108(13%)vs 45 Gy组14/116(12%);p=0.84。
- 3-4级放射性肺炎:54 Gy组5/108(5%)vs 45 Gy组7/116(6%);p=0.663。
- 治疗相关死亡:54 Gy组1例(心肌梗死),45 Gy组无报告。
- 研究于2021年4月30日因独立数据安全监查委员会认定临床获益充分而提前终止。
证据类型、等级与局限
- 证据类型:多中心、开放标签、3期随机试验。
- 研究在ClinicalTrials.gov注册,注册号NCT03214003。
- 研究提前终止(独立数据安全监查委员会认定临床获益充分)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与标准剂量胸部放疗(45 Gy)相比,高剂量放疗(54 Gy)在18-70岁局限期小细胞肺癌患者中改善总生存且未增加毒性。
- 作者结论支持将每日两次加速胸部放疗(54 Gy)联合化疗作为局限期小细胞肺癌一线替代治疗选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: For the past 20 years, twice-daily thoracic radiotherapy with concurrent chemotherapy has been the treatment of choice for limited-stage small-cell lung cancer (LS-SCLC), which has a poor prognosis. We aimed to assess the efficacy and safety of high-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) versus standard-dose radiotherapy (45 Gy in 30 fractions) as a first-line treatment for LS-SCLC.
METHODS: This open-label, randomised, phase 3 trial was performed at 16 public hospitals in China. The key inclusion criteria were patients aged 18-70 years, with histologically or cytologically confirmed LS-SCLC, who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and who were previously untreated or had received one course of cisplatin or carboplatin and etoposide. Eligible patients were randomly assigned (1:1) to receive volumetric-modulated arc radiotherapy (VMAT) of 45 Gy in 30 fractions to the gross tumour volume or VMAT with a simultaneous integrated boost of 54 Gy in 30 fractions to the gross tumour volume starting 0-42 days after the first chemotherapy course. Both groups received 10 fractions of twice-daily thoracic radiotherapy per week. The planning target volume was 45 Gy in 30 fractions in both groups. Patients with responsive disease received prophylactic cranial radiotherapy (25 Gy in 10 fractions). Randomisation was performed using a centralised interactive web response system, stratified by ECOG performance status, disease stage, previous chemotherapy course, and chemotherapy choice. The primary outcome was overall survival in the intention-to-treat population. Safety was analysed in the as-treated population. This study was registered at ClinicalTrials.gov, NCT03214003.
FINDINGS: From June 30, 2017, to April 6, 2021, 224 patients (102 [46%] females and 122 [54%] males; median age 64 years [IQR 58-68]) were enrolled and randomly assigned to the 54 Gy group (n=108) or 45 Gy (n=116) group. The median follow-up was 46 months (IQR 33-56). The median overall survival was significantly longer in the 54 Gy group (60·7 months [95% CI 49·2-62·0]) than in the 45 Gy group (39·5 months [27·5-51·4]; hazard ratio 0·55 [95% CI 0·37-0·72]; p=0·003). Treatment was tolerable, and the chemotherapy-related and radiotherapy-related toxicities were similar between the groups. The grade 3-4 radiotherapy toxicities were oesophagitis (14 [13%] of 108 patients in the 54 Gy group vs 14 [12%] of 116 patients in the 45 Gy group; p=0·84) and pneumonitis (five [5%] of 108 patients vs seven [6%] of 116 patients; p=0·663). Only one treatment-related death occurred in the 54 Gy group (myocardial infarction). The study was prematurely terminated by an independent data safety monitoring board on April 30, 2021, based on evidence of sufficient clinical benefit.
INTERPRETATION: Compared with standard-dose thoracic radiotherapy (45 Gy), high-dose radiotherapy (54 Gy) improved overall survival without increasing toxicity in a cohort of patients aged 18-70 years with LS-SCLC. Our results support the use of twice-daily accelerated thoracic radiotherapy (54 Gy) with concurrent chemotherapy as an alternative first-line LS-SCLC treatment option.
FUNDING: Chinese Society of Clinical Oncology-Linghang Cancer Research, the Wu Jieping Medical Foundation, and Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital and Beijing Municipal Administration of Hospitals Incubating Program.
参考来源
- Yu J, Jiang L, Zhao L, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. 2024. PMID: 39146944. doi:10.1016/S2213-2600(24)00189-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。